Screener / SEC EDGAR /CIK 0001178670 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Alnylam Pharmaceuticals, Inc. ALNY

Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. 10-K, Item 1

Employees
2,500
Headquarters
Cambridge, MA
CEO
Yvonne Greenstreet
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $3.7B through the costs to a net profit of $313.7M · income statement of the 10-K

14% operating margin
Revenue to Gross profit: $3.0BRevenue to Cost of revenue: $677.2MGross profit to Operating profit: $501.6MGross profit to Operating expenses: $2.5BOperating profit to Net profit: $313.7MOperating profit to Tax & other: $187.8MOperating expenses to R&D: $1.3BOperating expenses to SG&A: $1.2B Revenue: $3.7B REVENUE $3.7B +65% Y/Y Gross profit: $3.0B · 82% margin GROSS PROFIT $3.0B 82% margin Cost of revenue: $677.2M · 18% of revenue COST OF REVENUE $677.2M 18% of revenue Operating profit: $501.6M · 14% margin OPERATING PROFIT $501.6M 14% margin Operating expenses: $2.5B · 68% of revenue OPERATING EXPENSES $2.5B 68% of revenue Net profit: $313.7M · 8% margin NET PROFIT $313.7M 8% margin Tax & other: $187.8M · 5% of revenue TAX & OTHER $187.8M 5% of revenue R&D: $1.3B · 36% of revenue R&D $1.3B 36% of revenue SG&A: $1.2B · 33% of revenue SG&A $1.2B 33% of revenue
Gross profit $3.0B 82% margin
Operating profit $501.6M 14% margin
Net profit $313.7M 8% margin
The full income statement, year by year

ALNY among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 65.2%, above 93% of 154 peers (their median 10.4%) REVENUE GROWTH 65.2% · above 93% Gross margin: 77.4%, above 81% of 107 peers (their median 63.4%) GROSS MARGIN 77.4% · above 81% Operating margin: 19.5%, above 77% of 138 peers (their median 9.8%) OPERATING MARGIN 19.5% · above 77% Net margin: 52.8%, above 99% of 153 peers (their median 6.7%) NET MARGIN 52.8% · above 99% FCF margin: 16.1%, above 69% of 144 peers (their median 9.9%) FCF MARGIN 16.1% · above 69% Return on capital: 13.5%, above 78% of 89 peers (their median 9.0%) RETURN ON CAPITAL 13.5% · above 78%
ALNY Peer median Below the median

What changed

53 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 12, 2026 against Feb 13, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +91.8% ($405.3M to $777.6M) vs revenue +65.2% ($2.2B to $3.7B), +26.7 pts apart
  • Cash from operations $524.1M vs net income $313.7M (FY ending Dec 31, 2025)
9 more checks with nothing to note
  • Inventory +5.4% ($78.5M to $82.7M) vs revenue +65.2% ($2.2B to $3.7B), -59.8 pts apart
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Liability Related to Sale of Future Royalties - Leqvio
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

53 paragraphs in Risk Factors that were not in the 10-K filed Feb 13, 2025. Quoted as filed.

All 53 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    If we are unable to sustain and grow revenues from sales of AMVUTTRA, our business would be materially harmed, our future operating results would be adversely impacted, and the market price of our common stock would likely decline. In 2025, a significant portion of our net product revenues was derived from the sale of our TTR products,…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    We may have difficulty continuing to expand our global operations successfully at the scale necessary to support our Alnylam 2030 ambitions.
  3. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    Any funding, personnel, policy or other disruptions at the FDA and other agencies may also delay those agencies’ review and response to our or our collaborators’ regulatory submissions, which would adversely affect our business. For example, over
  4. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    Our six marketed products, including two products that are commercialized by collaborators, and any product candidates for which we or our collaborators may ultimately receive marketing authorization, are subject to ongoing regulatory

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.0B$1.8B$2.2B$3.7B
Net income−$1.1B−$440.2M−$278.2M$313.7M
Operating cash flow−$541.3M$104.2M−$8.3M$524.1M
Free cash flow−$613.3M$41.9M−$42.6M$465.4M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$3.7B ▲ 65.2% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

6 filings in the last 30 days · SEC EDGAR

All filings
1 more

About the company

Alnylam Pharmaceuticals, Inc., Cambridge, MA · from the 10-K filed Feb 12, 2026

Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics.

Headquarters
Cambridge, MA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Oct 29, 2026

Employees, at the top of the page: "As of December 31, 2025, we employed approximately 2,500 full-time employees, of whom approximately 1,945 were employed in the U" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 12, 2026 (open at SEC), compared with the 10-K filed Feb 13, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALNY/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.